

# Resource Summary Report

Generated by [NIF](#) on Sep 4, 2026

## MIT Center for Biomedical Innovation

RRID:SCR\_004027

Type: Tool

### Proper Citation

MIT Center for Biomedical Innovation (RRID:SCR\_004027)

### Resource Information

**URL:** <http://cbi.mit.edu/>

**Proper Citation:** MIT Center for Biomedical Innovation (RRID:SCR\_004027)

**Description:** Consortium formed to improve global health by overcoming obstacles to the development and implementation of biomedical innovation. CBI provides a safe and transparent environment for collaborative research among industry, academia, and government, and draws on the expertise of the Massachusetts Institute of Technology's (MIT) Schools of Engineering, Science, and Management, as well as the Harvard-MIT Division of Health Sciences and Technology (HST). The center manages several consortia addressing a variety of challenges in the global biomedical industry by developing, testing, and disseminating new knowledge and tools designed for real world application through the following programs: the Biomanufacturing Program (BioMAN), the Consortium on Adventitious Agents in Biomanufacturing (CAACB), and New Drug Development Paradigms (NEWDIGS). The consortia managed by CBI include: \* Biomanufacturing (BioMAN): a collaborative research and educational program in biotherapeutic manufacturing. The objective is to develop new knowledge, science, technologies and strategies that advance the manufacture and global delivery of high quality biopharmaceuticals. BioMAN activities bring together thought leaders from industry, the government/FDA and academia and involve faculty from across the Schools of Science, Engineering and Management at MIT \* Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB): Their mission is to develop a comprehensive understanding of adventitious agents encountered in biomanufacturing, the sources of such agents, and a systematic, risk-based analysis of the most effective strategies and technologies to prevent contamination. \* NEW Drug Development ParaDIGmS (NEWDIGS): focuses on transforming the current global pharmaceutical innovation ecosystem to more reliably and sustainably deliver new, better, affordable drugs to the right patients faster. System re-engineering projects are designed and executed with input from industry; regulators from US, Europe, Singapore, and Canada; payers and health technology assessment officials; providers, patients, and academic researchers from MIT, Harvard and other leading academic institutions.

**Abbreviations:** MIT CBI, CBI

**Synonyms:** Center for Biomedical Innovation

**Resource Type:** consortium, data or information resource, organization portal, portal

**Keywords:** biomedical innovation, biomedical, innovation, biomanufacturing, biopharmaceutical, pharmaceutical, drug development, product development, tool development, clinical trial, drug, biotechnology, diagnostics, medical device

**Funding:** government ;  
industry ;  
philanthropic organizations ;  
Massachusetts Institute of Technology; Massachusetts; USA ;  
School of Science ;  
the School of Engineering ;  
the MIT Sloan School of Management ;  
Office of the Provost ;  
Office of the Vice President for Research and Associate Provost ;  
MTC/JAI ;  
Merck Company Foundation ;  
Membership fees

**Resource Name:** MIT Center for Biomedical Innovation

**Resource ID:** SCR\_004027

**Alternate IDs:** nlx\_158454

**Record Creation Time:** 20220129T080222+0000

**Record Last Update:** 20260903T235740+0000

---

## Ratings and Alerts

No rating or validation information has been found for MIT Center for Biomedical Innovation.

No alerts have been found for MIT Center for Biomedical Innovation.

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We have not found any literature mentions for this resource.